Cargando…

Glycan and Peptide IgE Epitopes of the TNF-alpha Blockers Infliximab and Adalimumab - Precision Diagnostics by Cross-Reactivity Immune Profiling of Patient Sera

Biological drugs like therapeutic antibodies are widely used for the treatment of various diseases like inflammatory disorders and cancer. A drawback of these novel treatments is the substantial proportion of patients experiencing adverse reactions such as loss-of-drug effect or hypersensitivity rea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Homann, Arne, Röckendorf, Niels, Kromminga, Arno, Frey, Andreas, Platts-Mills, Thomas A, Jappe, Uta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706093/ https://www.ncbi.nlm.nih.gov/pubmed/29187897 http://dx.doi.org/10.7150/thno.20654

Ejemplares similares

B cell epitopes on infliximab identified by oligopeptide microarray with unprocessed patient sera
por: Homann, Arne, et al.
Publicado: (2015)

IgE Epitope Profiling for Allergy Diagnosis and Therapy – Parallel Analysis of a Multitude of Potential Linear Epitopes Using a High Throughput Screening Platform
por: Krause, Thorsten, et al.
Publicado: (2020)

Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
por: Henry, Alistair I, et al.
Publicado: (2011)

Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab
por: Neovius, M, et al.
Publicado: (2015)

TNF-α Promoter Polymorphisms Predict the Response to Etanercept More Powerfully than that to Infliximab/Adalimumab in Spondyloarthritis
por: Liu, Jing, et al.
Publicado: (2016)

Anaphylactic reactions to pomegranate: identification and characterization of eliciting IgE-reactive components
por: Petersen, Arnd, et al.
Publicado: (2011)

Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn’s disease
por: Carlsen, Arne, et al.
Publicado: (2018)

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
por: Xie, Feng, et al.
Publicado: (2009)

Psoriatic Arthritis That Responded Dramatically When Infliximab Was Switched to Adalimumab
por: Ohshima, Yuichiro, et al.
Publicado: (2013)

Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
por: Im, Jong Pil
Publicado: (2017)

Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?
por: Kim, Eun Soo
Publicado: (2021)

Adalimumab/infliximab: Lower serologic response: 6 case reports
Publicado: (2022)

Systematic review of studies comparing infliximab and adalimumab in autoimmune uveitis
por: Mase, Oliver, et al.
Publicado: (2023)

Disseminated tuberculosis infection and paradoxical reaction during antimycobacterial treatment related to TNF-alpha blocker agent Infliximab
por: Unlu, Mehmet, et al.
Publicado: (2014)

Identification of Critical Amino Acids in the IgE Epitopes of Ric c 1 and Ric c 3 and the Application of Glutamic Acid as an IgE Blocker
por: Deus-de-Oliveira, Natalia, et al.
Publicado: (2011)

Infliximab-graded challenge in a patient with Crohn’s disease and adalimumab hypersensitivity
por: Song, Christine H, et al.
Publicado: (2012)

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
por: Kawalec, Paweł, et al.
Publicado: (2016)

Prolonged paradoxical reaction to anti-tuberculous treatment after discontinuation of TNF-alpha- blocker therapy with adalimumab. Rare clinical documentation
por: Falkenstern-Ge, Roger Fei, et al.
Publicado: (2014)

Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis
por: Hebeisen, Monika, et al.
Publicado: (2019)

Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease
por: Reinisch, Walter, et al.
Publicado: (2020)

Efficacy of infliximab and adalimumab therapy in very early onset, severe ulcerative colitis
por: Rohani, Pejman, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept
por: Gholami, Ahmad, et al.
Publicado: (2021)

Long-Term Clinical Remission in Biologically Naïve Crohn's Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab
por: Mizoshita, Tsutomu, et al.
Publicado: (2016)

A single glycan on IgE is indispensable for initiation of anaphylaxis
por: Shade, Kai-Ting C., et al.
Publicado: (2015)

In Planta Glycan Engineering and Functional Activities of IgE Antibodies
por: Montero-Morales, Laura, et al.
Publicado: (2019)

Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study
por: Barberio, Brigida, et al.
Publicado: (2020)

Use of Adalimumab in young patients with chronic uveitis in whom infliximab loses its efficacy
por: Giani, TG, et al.
Publicado: (2008)

Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study
por: Thorne, Carter, et al.
Publicado: (2017)

Immunoassay methods used in clinical studies for the detection of anti‐drug antibodies to adalimumab and infliximab
por: Gorovits, B., et al.
Publicado: (2018)

Clinical Impact of Corrections to Infliximab and Adalimumab Monitoring Results with the Homogeneous Mobility Shift Assay
por: Papamichael, Konstantinos, et al.
Publicado: (2020)

Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients
por: Campanilho-Marques, Raquel, et al.
Publicado: (2020)

Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study
por: Prens, L.M., et al.
Publicado: (2021)

Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis
por: Pan, Ran, et al.
Publicado: (2022)

Adalimumab/golimumab/infliximab: SARS-CoV-2 pneumonia: 3 case reports
Publicado: (2021)

The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab—Polish Experiences
por: Barszczewska, Olga, et al.
Publicado: (2021)

Corrigendum to: Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease
Publicado: (2021)

Comparative Evaluation of Four Commercially Available Immunoassays for Therapeutic Drug Monitoring of Infliximab and Adalimumab
por: Rissel, Florian, et al.
Publicado: (2023)

A General Method to Discover Epitopes from Sera
por: Whittemore, Kurt, et al.
Publicado: (2016)

Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment
por: Suzuki, Taketo, et al.
Publicado: (2019)

IgE glycans promote anti-IgE IgG autoantibodies that facilitate IgE serum clearance via Fc Receptors
por: Plattner, Kevin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ggpqa03amhj8pqmp6ds3pelauh